October 23, 2019 / 2:36 PM / a month ago

Eli Lilly to target cancer drug developers for deals

The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 18, 2018. REUTERS/Brendan McDermid/File Photo

(Reuters) - Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.

“Probably because of the number of opportunities, you will see us active in oncology - that’s where a lot of early stage biotech is,” Ricks said.

Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below